Telormedix appoints new chairman

Nicholas Rogerson has taken the role

Telormedix, a Swiss clinical stage biopharmaceutical company focused on TLR7 agonists in the treatment of cancer and inflammatory diseases, has appointed Nicholas Ralphe Rogerson as chairman.

Rogerson has worked in the pharmaceutical industry for nearly 25 years in major companies, as well as in consulting and investment banking. He specialises in business development and advises pharma and biotech companies, investment banks and venture capitalists on issues such as partnering, M&A and strategic exits.

Following an early scientific career, Rogerson started in regulatory affairs and progressed to business development. He has been global head of pharmaceutical business development at Hoffmann-La Roche, head of corporate M&A for Novartis and md of Bear Stearns, leading its European Pharma M&A efforts.

You may also like

Finance

Merck to acquire cancer biotech Terns Pharmaceuticals for $6.7bn

The purchase is the third multibillion-dollar acquisition for the pharma giant in the past year, as it moves to bolster its cancer portfolio ahead of its best-selling drug Keytruda losing patent protection in 2028
Marketing

Indena to highlight expanded HPAPI, ADC and peptide drug conjugate capabilities at DCAT Week 2026

Italian CDMO Indena will showcase its high-potency API manufacturing expertise and growing oncology-focused capabilities at DCAT Week in New York, including ten commercial HPAPIs in production and advancing work in antibody-drug and peptide drug conjugates
Manufacturing

Wilmington PharmaTech invests $50m into US small-molecule API manufacturing plant

The CRDMO will more than double the capacity in its current API reactor in Delaware, positioning itself to meet growing demand for US-based manufacturing
Manufacturing

Nulogy launches Supplier Compliance Management to build stronger, more resilient supplier networks

Nulogy, a leading provider of manufacturing operations software, announced the launch of Nulogy Supplier Compliance Management, a solution designed to centralise and automate supplier compliance for procurement, supply chain, and quality assurance teams in manufacturing, food & beverage, pharmaceuticals, and other highly regulated industries
Regulatory

The challenges of developing combination products

Regulatory complexity and the case for a holistic development strategy
Ingredients

dsm-firmenich launches ModulaSENSE Bitter to tackle bitterness in oral drug formulations

The new taste modulation technology combines bitter blockers, maskers and sweeteners with receptor-based analysis to help pharmaceutical formulators improve the palatability of oral medicines
You need to be a subscriber to read this article.
Click here to find out more.
Analysis

Semaglutide patent cliff: pharma industry braces for impact

With the weight-loss industry shifting from a monopoly held by innovators to a high-volume, competitive generic market, the pharma manufacturing sector is gearing up for a "generic wave" with investments into large-scale protein synthesis and facilities for injectables
Subscribe now